Human microbiome strategic business research report 2024: global market to reach $2.8 billion by 2030 from $486 million in 2023, driven by dow, dupont de nemours, and enterome among others

Understand the significant growth trajectory of the gastrointestinal diseases segment, which is expected to reach us$1.3 billion by 2030 with a cagr of a 28.7%. the endocrine & metabolic disorders segment is also set to grow at 23.6% cagr over the analysis period. gain insights into the u.s. market, which was valued at $141.2 million in 2023, and china, forecasted to grow at an impressive 27.4% cagr to reach $417.6 million by 2030. discover growth trends in other key regions, including japan, canada, germany, and the asia-pacific. understand the significant growth trajectory of the gastrointestinal diseases segment, which is expected to reach us$1.3 billion by 2030 with a cagr of a 28.7%. the endocrine & metabolic disorders segment is also set to grow at 23.6% cagr over the analysis period. gain insights into the u.s. market, which was valued at $141.2 million in 2023, and china, forecasted to grow at an impressive 27.4% cagr to reach $417.6 million by 2030. discover growth trends in other key regions, including japan, canada, germany, and the asia-pacific.
DD Ratings Summary
DD Quant Ranking